Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
The Annals of Family MedicinePublished 1 March 2007Open access
Ira L Mintzer, Matthew D. Eisenberg, Maartje Terra, Casey Z. MacVane, David U. Himmelstein, Steffie Woolhandler
Citations118
SJR quartileQ1
SJR score1.10
SNIP1.69
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings with limited on-site resources.
Abstract
Opioid-addicted patients can be safely and effectively treated in non-research primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.
Keywords
Medicine
Cochrane Database of Systematic ReviewsBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
2,250 Citations2014Richard P. Mattick, Courtney Breen +2 more
Buprenorphine maintenance compared to placebo and to methadone maintenance in the management of opioid dependence, including its ability to retain people in treatment, suppress illicit drug use, reduce criminal activity, and mortality is evaluated.
New England Journal of MedicineOffice-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone
583 Citations2003Paul J. Fudala, T. Peter Bridge +14 more
JAMAA Controlled Trial of Buprenorphine Treatment for Opioid Dependence
563 Citations1992Rolley E. Johnson
Buprenorphine was as effective as methadone, 60 mg/d, and both were superior to methad one, 20 mg/D, in reducing illicit opioid use and maintaining patients in treatment for 25 weeks.
JAMAA controlled trial of buprenorphine treatment for opioid dependence
199 Citations1992Rolley E. Johnson
The American Journal of MedicineA randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic
176 Citations1998PatrickG O’Connor, AlisonH Oliveto +7 more
Buprenorphine maintenance is an effective treatment for heroin dependence in a primary care setting and may be effective on a thrice weekly basis.
Journal of General Internal MedicineBrief report: Buprenorphine retention in primary care
172 Citations2005Michael D. Stein, Patricia A. Cioe +1 more
Abstinence during the first week of treatment and receipt of counseling were critical to patient retention, and retention rates in a real world, primary care-based buprenorphine maintenance practice reflect those reported in clinical trials.
Cochrane Database of Systematic ReviewsBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
167 Citations2003RP Mattick, Jo Kimber +2 more
PubMedContinuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992.
166 Citations1994Don C. Des Jarlais, Samuel R. Friedman +7 more
JAMAContinuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992
147 Citations1994Don C. Des Jarlais
Drug and Alcohol DependenceBuprenorphine: a controlled clinical trial in the treatment of opioid dependence
131 Citations2000P. Pani
AddictionA randomized controlled trial of buprenorphine in the management of short‐term ambulatory heroin withdrawal
103 Citations2002Nicholas Lintzeris, James Bell +3 more
Buprenorphine is effective for short-term ambulatory heroin withdrawal, with greater retention, less heroin use and less withdrawal discomfort during withdrawal; and increased postwithdrawal treatment retention than symptomatic medications.
Annals of Internal MedicineNew Federal Initiatives To Enhance the Medical Treatment of Opioid Dependence
98 Citations2002David A. Fiellin, Patrick G. O’Connor
The system by which the FDA regulates and monitors the use of opioid medications is too heavily oriented toward administrative requirements and focuses too little on treatment outcomes, which fault a regulatory system that promotes process-oriented evaluations that lack clinical orientation over medical judgment and patient outcomes.
Drug and Alcohol DependenceBuprenorphine: a controlled clinical trial in the treatment of opioid dependence
98 Citations2000Pier Paolo Pani, Icro Maremmani +3 more
The utility of buprenorphine for the treatment of opioid dependence is supported, and patients who dropped out differed significantly from those who stayed, in terms of a higher level of psychopathological symptoms, and a lower level of psychosocial functioning.
International Journal of EpidemiologyMortality of drug addicts in the United Kingdom 1967-1993
97 Citations1998Hamid Ghodse
It appears that service provision has some impact on all-causes mortality among opiate addicts, and as services improved, there was a corresponding decline in mortality rates during the study period.
Drug and Alcohol DependenceSafety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence
63 Citations2003T. Peter Bridge
There is a need to develop new pharmacotherapies for opiate dependence that extend the range of clinical options, including new first-line treatment approaches, based on data derived from clinical trials and post-marketing surveillance that provide evidence for the use of the medications as first- line treatments in an office-based environment.
NeurosignalsThe Role of Opioid Receptor Phosphorylation and Trafficking in Adaptations to Persistent Opioid Treatment
43 Citations2005Emma E. Johnson, MacDonald J. Christie +1 more
As receptor phosphorylation and resensitization appear to maintain continued signaling through the µ-opioid receptor, these two events are crucial in facilitating adaptations to chronic opioid treatment, and the possibility that agonist-specific phosphate can contribute to the development of different adaptations remains open.